Oric Pharmaceuticals initiated with a Buy at JonesResearch

JonesResearch initiated coverage of Oric Pharmaceuticals (ORIC) with a Buy rating and $17 price target Oric is focused on developing clinical stage targeted therapeutics to overcome resistance in genetically defined lung cancer and in broad metastatic prostate cancer patients, the analyst tells investors in a research note. The firm sees “see clear signs of differentiation with specificity, breadth of mutation coverage and safety profile.”